Why the Dimerix (ASX:DXB) share price is surging 6% higher today

The Dimerix (ASX: DXB) share price is surging higher today after the company announced a second clinical study for its lead drug candidate.

The Dimerix Ltd (ASX: DXB) share price lifted higher today after the company announced the start of its second clinical study on lead drug candidate, DMX-200. At the time of writing, the Dimerix share price is up 6.1% at 26 cents.

Young doctor raising arms in air with hands in fists celebrating a new development.

Image source: Getty Images

What's driving the Dimerix share price?

The Dimerix share price is storming higher following the announcement of its international study into COVID-19 patients. Led by Professor Meg Jardine at the University of Sydney Australia, the clinical trial will collaborate with Professor Vivek Jha and The George Institute for Global Health, in India.

DMX-200 was chosen for a partner study of the controlled evaluation of angiotensin receptor blockers for COVID-19 respiratory disease (Clarity) study. The Clarity 2.0 will seek to monitor the treatment of DMX-200 in COVID-19 patients who are admitted to hospital.

The phase 3, Clarity 2.0 study will assess roughly 600 patients in India who have tested positive for coronavirus, using DMX-200 together with an angiotensin receptor blocker. The randomised, double blind, controlled study will use the World Health Organisation's (WHO) 7-point health score. At the 14-day treatment day mark, Dimerix will record the primary endpoint results. Recruits in the study will be administered the drug for a period of up to 28 days and followed up for a total of 6 months.

The DMX-200 aims to reduce damage from inflammatory immune cells by blocking signals and limiting movement predominately in the lungs. When infected with COVID-19, patients usually suffer from breathing complications, prior to the onset of acute respiratory distress syndrome.

What did management say?

Commenting on the potential applications of DMX-200, Professor Meg Jardine said:

We generally see that people with chronic health conditions that include inflammatory drivers, such as chronic kidney disease, diabetes, cardiovascular disease and obesity, are also those who are more vulnerable to respiratory complications if they contract the SARS-CoV2 virus. Some of those inflammatory drivers interact with the blood pressure system which is why some common blood pressure medications may improve outcomes in COVID-19 disease.

Early results suggest that DMX-200 may have stronger anti-inflammatory effects when used in combination with these blood pressure medications. The Clarity and Clarity 2.0 studies are designed to answer whether these blood pressure medications, used alone or in combination with DMX-200, may alter the course of COVID-19 disease and provide a better outcome for patients.

Dimerix CEO and managing director Dr Nina Webster added:

Our lead candidate, DMX-200, has demonstrated efficacy across three different studies in patients with active inflammatory disease, and we are very pleased to support a second research study in COVID-19 patients as well as progressing DMX-200 into a Phase 3 clinical study in the rare kidney disease Focal Segmental Glomerulosclerosis (FSGS) in the first half of 2021.

About the Dimerix share price

The Dimerix share price hit an all-time high of 78 cents in September, but is still a long way off that level despite today's rise. Sitting at 26 cents, the Dimerix share price is up 100% since the beginning of the year.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

Sad man sitting at desk and grabbing his head as he looks at a laptop.
ASX Share Market News

These are the 10 most shorted ASX shares

Short sellers are targeting these shares this week. Let's find out why.

Read more »

Woman looking at her computer and pondering something.
ASX Share Market News

5 things to watch on the ASX 200 on Monday

Will the market start the week strongly? Here's what you need to know.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A geeky-looking young man with glasses bites down onto a computer keyboard in frustration or despair.
ASX Share Market News

Tech shares led the ASX 200 amid NVIDIA scandal and Microsoft outage last week

Xero's 1H FY27 results and a strong lead from Wall Street pushed the tech sector higher.

Read more »

Piles of increasing coins alongside an hourglass.
Opinions

Why I'm planning to buy more Soul Patts shares in 2027

I think Soul Patts is a great long-term buy.

Read more »

a close up of a woman's face looks skywards as she is showered in a sea of graphic symbols of gold and silver coins bearing the bitcoin logo.
Cryptocurrencies

Are you a 'greater fool' for owning Bitcoin?

Is Bitcoin truly an investment?

Read more »

IPO written in purple on blocks on top of each other in the air.
IPOs

Anthropic IPO: Are 5 types of shares too many?

Anthropic is going for a very unusual setup.

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Broker Notes

Buy, hold, sell: Resmed, Goodman Group, CBA shares

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities.

Read more »